Nectar Lifesciences Limited
Bombay Stock ExchangeTotal Valuation
Nectar Lifesciences Limited carries a market capitalization of 2.71B, placing it among publicly traded companies globally. Its enterprise value stands at 119.47M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.71B |
| Enterprise Value | 119.47M |
Share Statistics
Nectar Lifesciences Limited currently has 194.26M shares outstanding.
| Shares Outstanding | 194.26M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.71, and the price-to-book ratio stands at 10.45.
| PE Ratio | N/A |
| PS Ratio | 0.71 |
| PB Ratio | 10.45 |
| P/TBV Ratio | 0.35 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 0.04 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 0.64 |
Financial Position
Nectar Lifesciences Limited maintains a current ratio of 8.40, meaning it holds 8.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 8.40 |
| Quick Ratio | 6.35 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -2.52 |
Financial Efficiency
| Return on Equity (ROE) | -37.06 |
| Return on Assets (ROA) | -8.78 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.77 |
Taxes
| Income Tax | -644.42M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Nectar Lifesciences Limited's stock has declined approximately -50.10309% over the past 52 weeks. The 50-day moving average sits at 17.84, while the 200-day moving average is 18.11.
| Beta (5Y) | N/A |
| 52-Week Price Change | -50.10309% |
| 50-Day Moving Average | 17.84 |
| 200-Day Moving Average | 18.11 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Nectar Lifesciences Limited generated 2.86B in revenue and converted that into -1.17B in net income, yielding earnings per share of -1.52. EBITDA reached -1.38B, while operating income came in at -1.38B.
| Revenue | 2.86B |
| Gross Profit | 187.68M |
| Operating Income | -1.38B |
| Pretax Income | -975.88M |
| Net Income | -1.17B |
| EBITDA | -1.38B |
| EBIT | -1.38B |
| Earnings Per Share (EPS) | -1.52 |
Balance Sheet
Total book value stands at 194.26M, with working capital of 2.23B providing operational flexibility.
| Cash & Cash Equivalents | 1.91B |
| Total Debt | N/A |
| Net Debt | -1.12B |
| Equity (Book Value) | 194.26M |
| Book Value Per Share | 0.89 |
| Working Capital | 2.23B |
Margins
Nectar Lifesciences Limited operates with a gross margin of 6.57, reflecting its pricing power and cost economics. The operating margin of -48.40 and net profit margin of -41.03 provide insight into operational efficiency.
| Gross Margin | 6.57 |
| Operating Margin | -48.40 |
| Pretax Margin | -34.16 |
| Profit Margin | -41.03 |
| EBITDA Margin | -48.40 |
Stock Splits
Nectar Lifesciences Limited's most recent stock split took place on November 12, 2008 with a 1:10 split ratio.
| Last Split Date | 11/12/2008 |
| Split Ratio | 1:10 |
Scores
Nectar Lifesciences Limited posts an Altman Z-Score of 3.26, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.26 |